4 May 2022 , 08:33 AM
Biocon announced that the Health Products Regulatory Authority (HPRA), Ireland, conducted a GMP inspection of one of Biocon Biologics new monoclonal antibody drug substance manufacturing facilities in Biocon Park, Bengaluru, India, between 28 March and 01 April 2022.
The inspection report contains no critical observations and only one of the deficiencies is categorized as major which is being addressed expeditiously in consultation with the regulatory agency
Powered by Capital Market – Live News
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
